Maureen Smythe, Pharm.D.

Maureen Smythe, Pharm.D.

Professor (Clinical)

Office Location

EACPHS, Room 4126

Phone

313-577-5384

Email

msmythe@beaumont.edu

Department

Pharmacy Practice

Research website

https://orcid.org/0000-0002-5978-3770

Maureen Smythe, Pharm.D.

Degrees and Certifications

  • 1988 - Critical Care Fellowship, Wayne State University
  • 1988 - Pharm.D., Wayne State University
  • 1986 - B.S. Pharmacy, Wayne State University

Positions and Employment

  • 2017-present - Clinical Pharmacy Specialist- Anticoagulation, Beaumont
  • 2001-present - Professor of Pharmacy (Clinical)
  • 1988-present - Coordinator of Student Experiential Training at Beaumont
  • 2006 – 2017 - Director PGY1 Residency Program at Beaumont

Awards and Honors

  • 2017 - Wayne State University Distinguished Alumni Award
  • 2016 - Preceptor of Student Community Research Award
  • 2016 - WSU Student Research Awards
  • 2012 - Outstanding Achievement in Clinical Sciences Research, Wayne State University
  • 2007 - Preceptor of the Year, William Beaumont Hospital
  • 2005 - Teacher of the Year, Wayne State University, Professional 3rd year class
  • 2004 - Teacher of the Year, Wayne State University, Professional 3rd year class

Professional Memberships

  • American College of Clinical Pharmacy
  • Society of Critical Care Medicine through 2012
  • American Society of Health-System Pharmacists
  • Southeastern Michigan Society of Health-System Pharmacists

Areas of Expertise

  • Anticoagulation
  • Critical care therapeutics

Primary Research Interest

  • Anticoagulation management
  • Thrombosis
  • Critical care therapeutics

Recent Publications

Refereed Journals

  • Smythe MA, Koerber JM, Roberts AM, Hoffman JL, Batke J. Preventability of Hospital Acquired Venous Thromboembolism, submitted to Joint Commission, Journal on Quality and Patient Safety, submitted.
  • Smythe MA, Hoffman JL, Koerber JM, Mertz S, Fritsch K, Chehab F et al. Outcomes of activated prothrombin complex concentrate for direct Xa inhibitor bleeding; Thrombosis Research 2021; 206 142-144.
  • Smythe MA, Burns C, Liu Q, Garwood CL. Potential dexamethasone-direct oral anticoagulant drug interaction, is this a concern in COVID? Ann Pharmacother 2022; 56 (3):319-329
  • Warkentin TE, Smythe MA, Ali MA et al. Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT? Am J Hematol 2020; 1-10
  • Rimsans J, Douxfils J, Smythe MA, Gosselin C. Overview and application of coagulation assays in managing anticoagulation with direct oral anticoagulants, Current Pharmacol Report 2020;6:241-259
  • Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, Khan SR, RahmanM, Rajasekhar A, Rogers FB, Smythe MA, Tikkinen KAO, Yates AJ, Baldeh T Balduzzi S, Brozek JL, Ikobaltzeta IE, Johal H, Neumann I, Wiercioch W, Yepes, NunezJJ,Schunemann HJ, Dahm P. American Society of Hematology 2019 guidelines for the management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients, Blood Adv 2019; 3(23):3898-3944.
  • Smythe MA, Parker D Jr, Garwood CL, Cuker A, Messe SR. Timing of initiation of oral anticoagulation after acute ischemic stroke in patients with atrial fibrillation, Pharmacother 2019;10(3):23:389-44.

Abstracts

  • Mertz S, Chehab F, Koerber JM, Hoffman JL, Smythe MA. Anti-inhibitor coagulant complex for hemorrhage reversal in patients taking apixaban or rivaroxaban, Crit Care Med 2020,48 (1):241
  • Koerber JM, Fritsch K, Hoffman JL, Mertz S, Baalbaki N, Chehab F, Smythe MA. Characteristics, management and outcomes of patients receiving activated prothrombin complex concentrate for apixaban and rivaroxaban associated major bleeding, Am J Hematol 2020, In Press.

Courses taught by Maureen Smythe, Pharm.D.

Fall Term 2023

Fall Term 2022

← Return to listing